Stephen J. Freedland

Jul 17, 2024 | onclive.com | Stephen J. Freedland |Eleni Efstathiou

OpinionVideoJuly 17, 2024Author(s):Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case. Video content above is prompted by the following questions:What is your initial impression of this patient and their risk stratification? What biomarker testing and imaging would you recommend? How would you assess the burden and distribution of metastatic disease?

Jul 17, 2024 | onclive.com | Stephen J. Freedland |Eleni Efstathiou

OpinionVideoJuly 17, 2024Author(s):Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment. Video content above is prompted by the following questions:How do you foresee the early treatment paradigm for CSPC evolving in the coming years? Are there other novel agents you're excited about in development?

Jul 10, 2024 | onclive.com | Stephen J. Freedland |Eleni Efstathiou

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

Jul 10, 2024 | onclive.com | Stephen J. Freedland |Eleni Efstathiou

OpinionVideoJuly 10, 2024Author(s):Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients. Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment? At what PSA doubling time thresholds do treatment recommendations change?

Jul 3, 2024 | onclive.com | Stephen J. Freedland |Eleni Efstathiou

Author(s):Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer. Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?